Advertisement

Molecular Medicine

, Volume 18, Issue 2, pp 286–296 | Cite as

Functional Characterization of Glycine N-Methyltransferase and Its Interactive Protein DEPDC6/DEPTOR in Hepatocellular Carcinoma

  • Chia-Hung Yen
  • Yao-Cheng Lu
  • Chung-Hsien Li
  • Cheng-Ming Lee
  • Chia-Yen Chen
  • Ming-Yuan Cheng
  • Shiu-Feng Huang
  • Kuen-Feng Chen
  • Ann-Lii Cheng
  • Li-Ying Liao
  • Yan-Hwa Wu Lee
  • Yi-Ming Arthur Chen
Research Article

Abstract

Glycine N-methyltransferase (GNMT) is a tumor suppressor for hepatocellular carcinoma (HCC). High rates of Gnmt knockout mice developed HCC. Epigenetic alteration and dysregulation of several pathways including wingless-type MMTV integration site (Wnt), mitogen-activated protein kinase (MAPK) and Janus kinase and signal transducer and activator of transcription (JAK-STAT) are associated with HCC development in Gnmt knockout mice. We hypothesized that GNMT may regulate signal transduction through interacting with other proteins directly. In this report, we identified a mammalian target of rapamycin (mTOR) inhibitor (DEP domain containing MTOR-interacting protein [DEPDC6/DEPTOR]) as a GNMT-binding protein by using yeast two-hybrid screening. Fluorescence resonance energy transfer assay demonstrated that the C-terminal half of GNMT interact with the PSD-95/Dlg1/ZO-1 (PDZ) domain of DEPDC6/DEPTOR. Immunohistochemical staining showed that 27.5% (14/51) of HCC patients had higher expression levels of DEPDC6/DEPTOR in the tumorous tissues than in tumor-adjacent tissues, especially among HCC patients with hepatitis B viral infection (odds ratio 10.3, 95% confidence interval [CI] 1.05–11.3) or patients with poor prognosis (death hazard ratio 4.51, 95% CI 1.60–12.7). In terms of molecular mechanism, knockdown of DEPDC6/DEPTOR expression in HuH-7 cells caused S6K and 4E-BP activation, but suppressed Akt. Overexpression of DEPDC6/DEPTOR activated Akt and increased survival of HCC cells. Overexpression of GNMT caused activation of mTOR/raptor downstream signaling and delayed G2/M cell cycle progression, which altogether resulted in cellular senescence. Furthermore, GNMT reduced proliferation of HuH-7 cells and sensitized them to rapamycin treatment both in vitro and in vivo. In conclusion, GNMT regulates HCC growth in part through interacting with DEPDC6/DEPTOR and modulating mTOR/raptor signaling pathway. Both GNMT and DEPDC6/DEPTOR are potential targets for developing therapeutics for HCC.

Notes

Acknowledgments

We thank TLCN for providing the HCC tissue samples and related clinical data. This network currently includes five major medical centers (National Taiwan University Hospital, Chang-Gung Memorial Hospital-Linko, Veteran General Hospital-Taichung, Chang-Gung Memorial Hospital-Kaohsiung and Veteran General Hospital-Kaohsiung). TLCN was supported by grants from the National Science Council since 2005 (NSC 100-2325-B-182-006) and the National Health Research Institutes, Taiwan. In addition, we thank the Sequencing Core Facility of the National Yang-Ming University Genome Research Center and the Confocal Microscope Lab of National Taiwan University for technical support and for assistance in the FRET experiments. This work was supported in part by grants from the National Science Council of the Republic of China (National Research Program for Biopharmaceuticals [NRPB], grant NSC100-2325-B-010-008) and the Ministry of Education of the Republic of China (Aim for the Top University Plan).

Supplementary material

10020_2012_1802286_MOESM1_ESM.pdf (3.1 mb)
Supplementary material, approximately 3185 KB.

References

  1. 1.
    El-Serag HB, Rudolph KL. (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 132:2557–76.CrossRefGoogle Scholar
  2. 2.
    Finn RS. (2010) Development of molecularly targeted therapies in hepatocellular carcinoma: where do we go now? Clin. Cancer Res. 16:390–7.CrossRefGoogle Scholar
  3. 3.
    Llovet JM, Bruix J. (2008) Molecular targeted therapies in hepatocellular carcinoma. Hepatology. 48:1312–27.CrossRefGoogle Scholar
  4. 4.
    Sahin F, et al. (2004) mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin. Cancer Res. 10:8421–5.CrossRefGoogle Scholar
  5. 5.
    Villanueva A, et al. (2008) Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology. 135:1972–83.CrossRefGoogle Scholar
  6. 6.
    Lane HA, Breuleux M. (2009) Optimal targeting of the mTORC1 kinase in human cancer. Curr. Opin. Cell. Biol. 21:219–29.CrossRefGoogle Scholar
  7. 7.
    Sabatini DM. (2006) mTOR and cancer: insights into a complex relationship. Nat. Rev. Cancer. 6:729–34.CrossRefGoogle Scholar
  8. 8.
    Wullschleger S, Loewith R, Hall MN. (2006) TOR signaling in growth and metabolism. Cell. 124:471–84.CrossRefGoogle Scholar
  9. 9.
    Peterson TR, et al. (2009) DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell. 137:873–86.CrossRefGoogle Scholar
  10. 10.
    Liao YJ, et al. (2009) Characterization of a glycine N-methyltransferase gene knockout mouse model for hepatocellular carcinoma: implications of the gender disparity in liver cancer susceptibility. Int. J. Cancer. 124:816–26.CrossRefGoogle Scholar
  11. 11.
    Martinez-Chantar ML, et al. (2008) Loss of the glycine N-methyltransferase gene leads to steatosis and hepatocellular carcinoma in mice. Hepatology. 47:1191–9.CrossRefGoogle Scholar
  12. 12.
    Ogawa H, Fujioka M. (1982) Purification and properties of glycine N-methyltransferase from rat liver. J. Biol. Chem. 257:3447–52.PubMedGoogle Scholar
  13. 13.
    Cook RJ, Wagner C. (1984) Glycine N-methyltransferase is a folate binding protein of rat liver cytosol. Proc. Natl. Acad. Sci. U. S. A. 81:3631–4.CrossRefGoogle Scholar
  14. 14.
    Bhat R, Bresnick E. (1997) Glycine N-methyltransferase is an example of functional diversity: role as a polycyclic aromatic hydrocarbon-binding receptor. J. Biol. Chem. 272:21221–6.CrossRefGoogle Scholar
  15. 15.
    Chen SY, et al. (2004) Glycine N-methyltransferase tumor susceptibility gene in the benzo(a)pyrenedetoxification pathway. Cancer Res. 64:3617–23.CrossRefGoogle Scholar
  16. 16.
    Yen CH, et al. (2009) Glycine N-methyltransferase affects the metabolism of aflatoxin B1 and blocks its carcinogenic effect. Toxicol. Appl. Pharmacol. 235:296–304.CrossRefGoogle Scholar
  17. 17.
    Chen YM, et al. (2000) Genomic structure, expression, and chromosomal localization of the human glycine N-methyltransferase gene. Genomics. 66:43–7.CrossRefGoogle Scholar
  18. 18.
    Liu HH, et al. (2003) Characterization of reduced expression of glycine N-methyltransferase in cancerous hepatic tissues using two newly developed monoclonal antibodies. J. Biomed. Sci. 10:87–97.CrossRefGoogle Scholar
  19. 19.
    Jacinto E, et al. (2004) Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat. Cell. Biol. 6:1122–8.CrossRefGoogle Scholar
  20. 20.
    Yan Y, Marriott G. (2003) Analysis of protein interactions using fluorescence technologies. Curr. Opin. Chem. Biol. 7:635–40.CrossRefGoogle Scholar
  21. 21.
    Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. (1987) Evaluation of a tetrazoliumbased semiautomated colorimetric assay: assessment of radiosensitivity. Cancer Res. 47:943–6.PubMedGoogle Scholar
  22. 22.
    Dimri GP, et al. (1995) A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl. Acad. Sci. U. S. A. 92:9363–7.CrossRefGoogle Scholar
  23. 23.
    Augoustides-Savvopoulou P, et al. (2003) Glycine N-methyltransferase deficiency: a new patient with a novel mutation. J. Inherit. Metab. Dis. 26:745–59.CrossRefGoogle Scholar
  24. 24.
    Luka Z, Wagner C. (2003) Effect of naturally occurring mutations in human glycine N-methyltransferase on activity and conformation. Biochem. Biophys. Res. Commun. 312:1067–72.CrossRefGoogle Scholar
  25. 25.
    Baehrecke EH. (2005) Autophagy: dual roles in life and death? Nat. Rev. Mol. Cell. Biol. 6:505–10.CrossRefGoogle Scholar
  26. 26.
    Demidenko ZN, Blagosklonny MV. (2008) Growth stimulation leads to cellular senescence when the cell cycle is blocked. Cell. Cycle. 7:3355–61.CrossRefGoogle Scholar
  27. 27.
    Ruggero D, et al. (2004) The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat. Med. 10:484–6.CrossRefGoogle Scholar
  28. 28.
    Fu Z, et al. (1996) Crystal structure of glycine N-methyltransferase from rat liver. Biochemistry (Mosc). 35:11985–93.CrossRefGoogle Scholar
  29. 29.
    Tsai WL, Chung RT. (2010) Viral hepatocarcinogenesis. Oncogene. 29:2309–24.CrossRefGoogle Scholar
  30. 30.
    Wang J, Chenivesse X, Henglein B, Brechot C. (1990) Hepatitis B virus integration in a cyclin A gene in a hepatocellular carcinoma. Nature. 343:555–7.CrossRefGoogle Scholar
  31. 31.
    Yaginuma K, et al. (1987) Multiple integration site of hepatitis B virus DNA in hepatocellular carcinoma and chronic active hepatitis tissues from children. J. Virol. 61:1808–13.PubMedPubMedCentralGoogle Scholar
  32. 32.
    Horikawa I, Barrett JC. (2001) cis-Activation of the human telomerase gene (hTERT) by the hepatitis B virus genome. J. Natl. Cancer Inst. 93:1171–3.CrossRefGoogle Scholar
  33. 33.
    Ding Q, et al. (2005) Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin. Mol. Cell. 19:159–70.CrossRefGoogle Scholar
  34. 34.
    Lee AH, Iwakoshi NN, Anderson KC, Glimcher LH. (2003) Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc. Natl. Acad. Sci. U. S. A. 100:9946–51.CrossRefGoogle Scholar
  35. 35.
    Miller LL, Bly CG, Watson ML, Bale WF. (1951) The dominant role of the liver in plasma protein synthesis; a direct study of the isolated perfused rat liver with the aid of lysine-epsilon-C14. J. Exp. Med. 94:431–53.CrossRefGoogle Scholar
  36. 36.
    Ji C, Kaplowitz N. (2006) ER stress: can the liver cope? J. Hepatol. 45:321–33.CrossRefGoogle Scholar
  37. 37.
    Wang HC, et al. (2003) Different types of ground glass hepatocytes in chronic hepatitis B virus infection contain specific pre-S mutants that may induce endoplasmic reticulum stress. Am. J. Pathol. 163:2441–9.CrossRefGoogle Scholar
  38. 38.
    Liaw YF, Chu CM. (2009) Hepatitis B virus infection. Lancet. 373:582–92.CrossRefGoogle Scholar
  39. 39.
    Fine B, et al. (2009) Activation of the PI3K pathway in cancer through inhibition of PTEN by exchange factor P-REX2a. Science. 325:1261–5.CrossRefGoogle Scholar
  40. 40.
    Jasinghe VJ, et al. (2008) ABT-869, a multitargeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft. J. Hepatol. 49:985–97.CrossRefGoogle Scholar
  41. 41.
    Belham C, Comb MJ, Avruch J. (2001) Identification of the NIMA family kinases NEK6/7 as regulators of the p70 ribosomal S6 kinase. Curr. Biol. 11:1155–67.CrossRefGoogle Scholar
  42. 42.
    Lizcano JM, et al. (2002) Molecular basis for the substrate specificity of NIMA-related kinase-6 (NEK6): evidence that NEK6 does not phosphorylate the hydrophobic motif of ribosomal S6 protein kinase and serum- and glucocorticoid-induced protein kinase in vivo. J. Biol. Chem. 277:27839–49.CrossRefGoogle Scholar
  43. 43.
    Rao RD, Buckner JC, Sarkaria JN. (2004) Mammalian target of rapamycin (mTOR) inhibitors as anti-cancer agents. Curr. Cancer Drug Targets. 4:621–35.CrossRefGoogle Scholar
  44. 44.
    Carr BI, Kralian S. (2010) Molecular Targeted Therapies for HCC. In: Hepatocellular Carcinoma. Carr BI (ed.) Humana Press, New York, pp. 589–614.CrossRefGoogle Scholar
  45. 45.
    Huang YC, et al. (2007) Haplotypes, loss of heterozygosity, and expression levels of glycine N-methyltransferase in prostate cancer. Clin. Cancer Res. 13:1412–20.CrossRefGoogle Scholar
  46. 46.
    Edge SB, Compton CC. (2010) The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann. Surg. Oncol. 17:1471–4.CrossRefGoogle Scholar

Copyright information

© The Author(s) 2012

Authors and Affiliations

  • Chia-Hung Yen
    • 1
    • 9
  • Yao-Cheng Lu
    • 1
    • 9
  • Chung-Hsien Li
    • 1
    • 9
  • Cheng-Ming Lee
    • 1
    • 9
  • Chia-Yen Chen
    • 1
    • 9
  • Ming-Yuan Cheng
    • 2
    • 9
  • Shiu-Feng Huang
    • 3
    • 9
  • Kuen-Feng Chen
    • 4
    • 9
  • Ann-Lii Cheng
    • 5
    • 9
  • Li-Ying Liao
    • 6
    • 9
  • Yan-Hwa Wu Lee
    • 7
    • 9
  • Yi-Ming Arthur Chen
    • 1
    • 8
    • 9
  1. 1.AIDS Prevention and Research Center and Institute of Microbiology and Immunology, School of MedicineNational Yang-Ming UniversityShih-Pai, TaipeiTaiwan
  2. 2.Institute of Genome Sciences, School of Life SciencesNational Yang-Ming UniversityShih-Pai, TaipeiTaiwan
  3. 3.Division of Molecular and Genomic MedicineNational Health Research InstitutesMiaoliTaiwan
  4. 4.Department of Medical ResearchNational Taiwan University HospitalTaipeiTaiwan
  5. 5.Department of OncologyNational Taiwan University HospitalTaipeiTaiwan
  6. 6.Liver Center, Department of GastroenterologyTaipei City Hospital Renai BranchTaipeiTaiwan
  7. 7.Institute of Biological Science and Technology, Collage of Biological Science and TechnologyNational Chiao-Tung UniversityHsinchuTaiwan
  8. 8.Institute of Microbiology and Immunology, School of MedicineNational Yang-Ming UniversityShih-Pai, TaipeiTaiwan
  9. 9.VGH Genome Research CenterNational Yang-Ming UniversityShih-Pai, TaipeiTaiwan

Personalised recommendations